Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medica

Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including:9.29 Points for Patients at the Two-Year Milestone8.08 Points for Patients at the One-Year Milestone8.71 Points for Patients at the Six...

Related Keywords

Virginia ,United States ,Norfolk ,Eastern Virginia Medical School ,United Kingdom ,Irvine ,California ,Charing Cross ,Westminster ,London ,City Of ,David Dexter ,Robert Berman ,Jenene Thomas ,Vveno Medical Corporation ,Exchange Commission ,Charing Cross International Symposium ,Vveno Medical Corporation The Company ,Revised Venous Clinical Severity Score ,Improvement Per Patient ,Patients Showing Clinical Meaningful Benefit ,Weighted Average ,Eleven Months Post Surgery ,File Application Seeking Venovalve ,Medical Corporation ,Cross International Symposium ,Clinical Meaningful Benefit ,Chronic Venous Insufficiency ,Efficacy Results ,Long Term Results ,Bioprosthetic Valve ,Chronic Deep Venous Reflux ,Sentara Hospital ,Associate Professor ,Eastern Virginia Medical ,Private Securities Litigation Reform Act ,